ArticleFrontiers in artificial intelligence2026
GENESIS-SHIELD: an interpretable ensemble for anomaly detection in CRISPR genomic-workflow security.
Article in Frontiers in artificial intelligence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The rapid advancement of CRISPR-based gene editing has introduced digital-workflow security and integrity challenges: unauthorized modifications, temporal inconsistencies, and duplicated provenance records can compromise the auditability of editing logs. These are distinct from the biological risks of editing itself; our focus is the security of the Methods: We present GENESIS-SHIELD, a multi-component ensemble whose novelty lies in the Results: On a Discussion: These results are a proof-of-concept on rule-defined synthetic data; the high per-category detection reflects the benchmark's construction and does not establish real-world security. Validation on real editing logs, adversarial testing, and multi-objective coverage remain necessary before deployment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.